Roche Diagnostics announced that the FDA has cleared its cobas pro integrated solutions, a new generation of Serum Work Area (clinical chemistry and immunochemistry) laboratory solution, designed to optimize lab operations. With the cobas pro integrated solutions, laboratories are now able to run tests faster on less equipment, automate manual tasks and deliver results more quickly to aid in treatment decisions.
Diagnostic laboratories are a critical component of the global healthcare system with in vitro diagnostics influencing up to 70 percent of all clinical decisions while accounting for only about 2 percent of total healthcare spending. Together, medical and lab professionals play a key role in delivering optimal patient care, yet they face increasing pressure to manage a growing number of samples, while delivering quality results faster and rising profitability.
The latest innovation from Roche allows for up to 2,200 tests per hour with three modules working in parallel and synchronized to improve efficiency. Additionally, the cobas pro integrated solutions can boast up to 3¼ hours less operating time for a daily routine workload compared to cobas 6000 2,3, while 93 percent of Roche immunoassays have reaction times of 18 minutes or less. Reducing the time in delivering results to physicians and patients across a number of therapeutic areas including pregnancy, core lab/HIV testing and blood screening, is vital to clinical decision making.
